This announcement contains inside information for the purposes of article 7 of the Market Abuse Regulation (EU) 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

Trellus Health plc

("Trellus Health", the "Company" or the "Group")

Finance update

LONDON, U.K. AND NEW YORK, U.S. (24 November 2025). Trellus Health® plc (AIM: TRLS), a healthcare company delivering Trellus Elevate®, a digital platform that integrates data analytics with personalised, scientifically proven resilience programs and value-based solutions to manage complex chronic conditions, announces it has entered into a unsecured loan agreement with the Company's long standing substantial shareholder, Icahn School of Medicine at Mount Sinai ("Mount Sinai"), with a principal amount of US$600,000 (the "Loan Note").

Loan Note Terms

The Loan Note will be non-interest bearing for the first six months. Thereafter, it will accrue interest at an annual rate of 8%, payable in either new ordinary shares of 0.06 pence each ("Ordinary Shares") or cash, at the Company's discretion, upon conversion of the principal amount of the Loan Note.

The term of the Loan Note is 12 months, at which point the Company may elect to redeem, convert into Ordinary Shares, or apply a combination of both at a conversion price of 0.525 pence, being the 5-day mid-market price of the Company's shares ending on the business day prior to signing the Loan Note.

Under the terms of the Loan Note, any conversion into Ordinary Shares is subject to a cap preventing Mount Sinai from holding more than 29.9% of the Company's issued share capital. This restriction applies to both the principal and any accrued interest.

Cash Runway

The proceeds from the Loan Note will support the continued execution of the Company's commercial strategy and extend its near-term cash runway to late January 2026. The Company remains in active discussions regarding a potential equity fundraising to extend the cash runway further. While these discussions are at an advanced stage, there is no guarantee that they will be concluded successfully or within the required timeframe.

The Company continues to focus on securing additional commercial contracts with pharmaceutical companies and Contract Research Organizations ("CROs"). Illustrative contract values typically range in total between $500k and $1 million for pharma and between $150k and $500k for CROs, excluding performance incentive fees.

Related Party Transaction

The Loan Note is deemed to be related party transaction under AIM Rule 13 of the AIM Rules for Companies. Mount Sinai is a substantial shareholder holding 40,384,897 Ordinary Shares equal to 25.0% of the issued share capital of the Company. The Company's Directors (excluding those who are connected to Mount Sinai) consider, having consulted with the Nominated Adviser, Singer Capital Markets, that the terms of the related party transaction are fair and reasonable insofar as the shareholders of the Company are concerned.

Dr. Marla Dubinsky, Chief Executive Officer of Trellus Health, said: "We are extremely grateful for Mount Sinai's continued support, which enables us to focus on executing agreements with pharmaceutical companies and CROs. Over the past month, we have signed contracts with two leading global CROs, reaffirming both the value of our offering to the pharmaceutical sector and our ability to secure and deliver on partnerships with industry leaders in drug development and clinical research. We have already begun implementation for the Phase 2B and Phase 3 trials with these partners and expect to launch the initial TrialSet™ programs by year-end."

Enquiries:

About Trellus Health plc (www.trellushealth.com)

Trellus Health® (AIM: TRLS) is a healthcare company providing value-based innovative solutions and services, helping people with chronic conditions take control of their health through a proven, scientifically validated self-management solution and continuous, personalised support. Trellus Health's approach empowers patients to better navigate the emotional and physical challenges of their conditions, leading to significant cost savings, enhanced treatment adherence, and long-term, sustainable health outcomes.

Trellus Health® integrates its proprietary resilience-based methodology with the technology, tools, and expert coaching and educator team to deliver Trellus Elevate®, a whole-person technology-enhanced condition management platform. The Company is initially focusing on chronic costly GI conditions that have a high mental health burden, such as Inflammatory Bowel Disease (IBD). Among IBD patients, applying the Trellus Elevate® methodology resulted in over 90% fewer hospitalisations and a reduction of over 70% in emergency room visits. Given the common emotional and mental health struggles associated with a variety of chronic conditions and therapeutic areas, Trellus Health® considers its approach to have potential utility and demand across many conditions.

The Company also offers Trellus TrialSet™, a solution for pharmaceutical partners spanning clinical trials to commercialisation, applying the same validated resilience science and platform to support trial success and long-term patient engagement

The Company was founded by Icahn School of Medicine at Mount Sinai faculty members Marla C. Dubinsky, MD, and Laurie Keefer, PhD, both world-leading experts in treating both the physical and emotional impacts of IBD, with a combined 50 years of pioneering whole-person healthcare innovation. Both the founders continue to have a financial interest in the Company.

Shares in Trellus Health were admitted to trading on AIM in May 2021, under the ticker TRLS. For more information, visit: www.trellushealth.com